CytomX, Pfizer antibody drug deal is worth up to $635M

Pfizer and CytomX Therapeutics agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's Probody drug-development technology. The firms will conduct preclinical research, and Pfizer will get the rights to develop and market any chosen ADCs. The deal entitles CytomX to $25 million upfront and as much as $610 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · BioWorld (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ